---
title: Discovering Patterns in the Gut Microbiota Associated With the Risk of Stroke and the Outcome After a Stroke and Integration of These Data With Genomic Information to Find New Drug Targets and New Treatments to Improve Neurological Evolution and Functional Status of Stroke Patients.
nct_id: NCT04795687
overall_status: UNKNOWN
sponsor: "Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau"
study_type: OBSERVATIONAL
primary_condition: Ischemic Stroke
countries: Spain
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04795687.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04795687"
ct_last_update_post_date: 2021-09-21
last_seen_at: "2026-05-12T07:25:47.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Discovering Patterns in the Gut Microbiota Associated With the Risk of Stroke and the Outcome After a Stroke and Integration of These Data With Genomic Information to Find New Drug Targets and New Treatments to Improve Neurological Evolution and Functional Status of Stroke Patients.

**Official Title:** Association of Metagenomics and Transcriptomics With the Appearance and Evolution of an Ischemic Stroke

**NCT ID:** [NCT04795687](https://clinicaltrials.gov/study/NCT04795687)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 300
- **Lead Sponsor:** Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- **Collaborators:** Instituto de Salud Carlos III
- **Conditions:** Ischemic Stroke
- **Start Date:** 2020-07-15
- **Completion Date:** 2022-12-31
- **CT.gov Last Update:** 2021-09-21

## Brief Summary

The composition of the intestinal microbiota is associated with the risk of stroke and with post-stroke neurological evolution. At the same time, the genetics and epigenetics of each patient are associated with the composition of the intestinal microbiota. The study of the microbiome in stroke patients will allow finding new therapeutic targets for the treatment of stroke patients.

For the study, samples will be collected from those patients with ischemic stroke who come to the hospital while the study is being carried out, taking into account certain criteria: the patients must be over 18 years of age, have suffered an ischemic stroke (demonstrated by resonance or head CT), not have any additional serious illness or unstable medical condition, and not be included in clinical trials with neuroprotective drugs. On the other hand, the control group will be asymptomatic, and will be made up of people who have not previously suffered a stroke or a cardiovascular event and who do not have diseases that affect the digestive tract.

The main variables of the study are the risk of stroke and disability after a cerebrovascular accident (measured by mRS at 3rd month). Microbiota, genetic and epigenetic variables are also taken into account, such as the presence and levels of bacteria, dysbiosis, genetic polymorphisms and levels of methylation in CpG islands.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Patients with ischemic stroke (demonstrated by resonance or head CT).

Exclusion Criteria:

* Patients under 18 years of age.
* Additional serious illness or unstable medical condition.
* Inclusion in clinical trials with neuroprotective drugs.
```

## Arms

- **Ischemic stroke patients**
- **Control**

## Primary Outcomes

- **Risk of stroke and disability after a stroke** _(time frame: 3 months)_ — Use of the Modified Rankin Scale (mRS), evaluted from 0 to 6 (where higher scores mean worse outcome), to asses disability in patients who have suffered a stroke and comparison over time to check for recovery and degree of continued disability

## Locations (1)

- Institut de Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.institut de recerca hospital de la santa creu i sant pau|barcelona||spain` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04795687.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04795687*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*